HLB Life Science Co., Ltd. (KOSDAQ:A067630) agreed to acquire AIM Inc from Yong Ho Cho and others for KRW 101,900 million on May 31, 2022. Payment method includes : Cash payment and issuance of convertible bonds A. Cash payment: KRW 52,900 million - Down payment: KRW 10,000 million paid in cash on the date of signing the contract (May 31, 2022) - Balance: KRW 42,900 million will be paid in cash on the closing date of the transaction (scheduled for June 30, 2022) B. Issuance of convertible bonds: KRW 45,000 million - Substitute payment of total face value of KRW 45,000 million for the 10th convertible bonds issued by HLB Life Science Co., Ltd. Funding method: Funds for acquiring securities of other corporations (the 9th issuance of non-guaranteed public offering with bearer type bonds) and the 10th issuance of convertible bonds. For the year ending 2021, AIM Inc has revenues of KRW 166,874 million, total assets of KRW 89,214 million, net income of KRW 34,228 million and total common equity of KRW 52,107 million. The transaction is expected to close on June 30, 2022.